When was TriSalus Life Sciences founded?

TriSalus Life Sciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is TriSalus Life Sciences located?

TriSalus Life Sciences is headquartered in Westminster, United States. It is registered at Westminster,Colorado.

How many employees does TriSalus Life Sciences have?

As of Sep 30, 2026, the latest employee count at TriSalus Life Sciences is 132.

Is TriSalus Life Sciences a funded company?

TriSalus Life Sciences is a funded company, having raised a total of $83.4M across 12 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 26, 2011.

When was the latest funding round of TriSalus Life Sciences?

TriSalus Life Sciences' latest funding was a $***** Post IPO round on Apr 30, 2025, with participation from 2 investors.

What is the annual revenue of TriSalus Life Sciences?

Annual revenue of TriSalus Life Sciences is between $10M and $50M as on Dec 31, 2025

Where does TriSalus Life Sciences rank among its competitors?

TriSalus Life Sciences ranks 2nd amongst 108 active competitors, of which 36 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was RenovoRx, which secured $10M in Mar, 2026.

Who are the top competitors of TriSalus Life Sciences?

TriSalus Life Sciences' top competitors include Halozyme, RenovoRx and Lyra Therapeutics. Among them, RenovoRx secured the most recent funding round in March, 2026.

TriSalus Life Sciences - 2026 Company Profile, Funding, Competitors & Financials

TriSalus Life Sciences is a public company based in Westminster (United States), founded in 2009. It operates as a Developer of drug delivery devices to treat cancers. TriSalus Life Sciences has raised $83.4M in funding from investors like High Country Ventures, Partisan Management Group and MCG Capital. The company has 108 active competitors, including 36 funded and 22 that have exited. Its top competitors include companies like Halozyme, RenovoRx and Lyra Therapeutics.

Company Details

TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.

Website: trisaluslifesci.com
Social
Email ID: *****@trisaluslifesci.com
Registered Address: Westminster,Colorado

Key Metrics

Founded Year

2009

Location

Westminster, United States

Stage

Public

Total Funding

$83.4M in 12 rounds

Latest Funding Round

Post IPO, Apr 30, 2025, $*****

Investors

High Country Ventures & 8 more

Ranked

2^nd among 108 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

132 as on Sep 30, 2026

Similar Companies

Halozyme & 128 more

Exit Details

Public

View TriSalus Life Sciences' full profile

TriSalus Life Sciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Trisalus Life Sciences, Inc. CIN: 1826667 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-
TRISALUS LIFE SCIENCES, INC CIN: 27-0629393 , United States, Active	Dec 31, 2017	-	100 (As on Dec 31, 2021)	-
Surefire Medical, Inc. Dba Trisalus Life Sciences CIN: 270629393 , United States, Active	Dec 31, 1999	-	116 (As on Dec 31, 2024)	-

TriSalus Life Sciences got listed on Mar 19, 2021.

Click here to take a look at TriSalus Life Sciences's IPO in detail

TriSalus Life Sciences has raised a total funding of $83.4M over 12 rounds. Its first funding round was on Apr 26, 2011. Its latest funding round was a Post IPO round on Apr 30, 2025 for $*****. 2 investors participated in its latest round. TriSalus Life Sciences has 9 institutional investors.

Here is the list of recent funding rounds of TriSalus Life Sciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2025	9698976	Post IPO	4725370	2217503	3100102	6618097
Dec 17, 2024	1196669	Post IPO	5035125	9871193	1322105	4670302
Oct 05, 2022	9545683	Post IPO	2408497	4973196	2355927	5431700

Access funding benchmarks and valuations. Sign up today!

View details of TriSalus Life Sciences's funding rounds and investors

TriSalus Life Sciences' employee count trend

TriSalus Life Sciences has 132 employees as of Sep 26. Here is TriSalus Life Sciences's employee count trend over the years:

Employee count trend for TriSalus Life Sciences

Uncover TriSalus Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TriSalus Life Sciences include Halozyme, RenovoRx and Lyra Therapeutics. Here is the list of Top 10 competitors of TriSalus Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	67/100
2nd	TriSalus Life Sciences 2009, Westminster (United States), Public	Developer of drug delivery devices to treat cancers	$83.4M	Nantahala Capital Management, Tullis Health Investors ... & 7 others	67/100
3rd	RenovoRx 2009, Los Altos (United States), Public	Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs	$10.9M	Golden Seeds, Boston Scientific & 10 others	62/100
4th	Lyra Therapeutics 2005, Watertown (United States), Public	Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS)	$110M	Perceptive Advisors, HTIF & 9 others	61/100
5th	Delcath 1987, New York City (United States), Public	Speciality Pharmaceutical and medical device company focused on oncology	-	BVF Partners, Logos & 8 others	61/100
6th	Foresee Pharmaceuticals 2011, Taipei (Taiwan), Public	Developer of injectables and NCEs for cancer and chronic diseases	$32.5M	CDIB Capital Group, Vivo Capital & 4 others	59/100
7th	Luminate Medical 2019, Galway (Ireland), Series A	Developer of a medical device to prevent hair loss during chemotherapy	$50M	Artis Ventures, Elkstone & 12 others	57/100
8th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
9th	MedinCell 2002, Jacou (France), Public	Developer of a portfolio of long-acting injectables in various therapeutic areas	-	Credit Mutuel Equity, Wellington & 10 others	55/100
10th	Cellectar Biosciences 2002, Florham Park (United States), Acquired	Developer of phospholipid drug conjugates (PDC) to treat cancer	-	AIGH Capital Management, ADAR1 Capital Management ... & 9 others	54/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on TriSalus Life Sciences's competitors? Click here to see the top ones

TriSalus Life Sciences has made no investments or acquisitions yet.

Here is the latest report on TriSalus Life Sciences's sector:

Free

Oncology - Sector Report

Edition: September, 2026 (75 Pages)

View all reports related to TriSalus Life Sciences

Media has covered TriSalus Life Sciences for a total of 17 events in the last 1 year, 8 of them have been about company updates and 2 about people movement.